Corrigendum: Polymyxins and Their Potential Next Generation as Therapeutic Antibiotics

نویسندگان

چکیده

برای دانلود باید عضویت طلایی داشته باشید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Corrigendum: Melatonin and Nitrones As Potential Therapeutic Agents for Stroke

[This corrects the article on p. 281 in vol. 8, PMID: 27932976.].

متن کامل

Bacitracin, Glycopeptide Antibiotics, and the Polymyxins

Bacitracin and the polymyxins are polypeptide antibiotics. They are relatively toxic drugs and have had only limited use in chemotherapy until recently. Vancomycin, a glycopeptide, although not without side effects, is widely used.Teicoplanin is a new glycopeptide antibiotic that may be beneficial against certain infections caused by gram-positive organisms. The mechanisms of action of this gro...

متن کامل

Genetically engineered bacteriocins and their potential as the next generation of antimicrobials.

The discovery of penicillin by Fleming in 1928 was an historical milestone in the fight against infectious disease. Over the following fifty years, pharmaceutical companies discovered and developed over 100 antibiotics effective against a wide range of human pathogens. More recently, the dramatic rise in antibiotic-resistant pathogens has stimulated renewed efforts to identify, develop or redes...

متن کامل

Inhaled antibiotics beyond aminoglycosides, polymyxins and aztreonam: A systematic review.

We sought to evaluate published evidence regarding clinical or microbiological outcomes related to the use of inhaled antibiotics other than aminoglycosides, polymyxins and aztreonam. A systematic search of PubMed and Scopus databases as well as bibliographies of eligible articles was performed. In total, 34 eligible studies were identified. Among several inhaled β-lactams, ceftazidime was used...

متن کامل

Biosimilar, biobetter and next generation therapeutic antibodies

On November 18, 2010, the European Medicine Agency (EMA) released a draft guideline on similar medicinal products containing monoclonal antibodies (mAbs), following a workshop organized by the agency in London on July 2, 2009. The guideline discusses relevant animal model, non-clinical and clinical studies that are recommended to establish the similarity and the safety of a biosimilar compared ...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

ژورنال

عنوان ژورنال: Frontiers in Microbiology

سال: 2019

ISSN: 1664-302X

DOI: 10.3389/fmicb.2019.02275